In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Canada, Kye Pharmaceuticals, has announced that Health Canada has accepted ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of ...

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

The present framework limits co-lending to partnerships between banks and non-banking financial companies (NBFCs) to priority ...

The shadow of Grey’s Anatomy lies heavily over new Netflix medical drama Pulse. As with the seemingly immortal Grey’s – which ...

Japan emerged on Tuesday as the first major economy to secure priority tariff negotiations with Donald Trump, highlighting ...

Going out to eat? See which Collier County restaurants were rated best by inspectors, and which failed the test.